197 related articles for article (PubMed ID: 32499237)
1. Diabetes and coronary artery disease: not just a risk factor.
Grant PJ; Cosentino F; Marx N
Heart; 2020 Sep; 106(17):1357-1364. PubMed ID: 32499237
[No Abstract] [Full Text] [Related]
2. Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies.
Avogaro A; Barillà F; Cavalot F; Consoli A; Federici M; Mancone M; Paolillo S; Pedrinelli R; Perseghin G; Perrone Filardi P; Scicali R; Sinagra G; Spaccarotella C; Indolfi C; Purrello F
Nutr Metab Cardiovasc Dis; 2021 Jun; 31(6):1671-1690. PubMed ID: 33994263
[TBL] [Abstract][Full Text] [Related]
3. Metformin: effects on cardiovascular risk factors in patients with non-insulin-dependent diabetes mellitus.
Palumbo PJ
J Diabetes Complications; 1998; 12(2):110-9. PubMed ID: 9559489
[TBL] [Abstract][Full Text] [Related]
4. Concurrent blood pressure, glycemic and lipid control for the prevention of vascular complications of type II diabetes mellitus: a long overdue objective?
Athyros VG; Mitsiou EK; Tziomalos K; Karagiannis A; Mikhailidis DP
Curr Vasc Pharmacol; 2010 Jan; 8(1):1-4. PubMed ID: 20394107
[No Abstract] [Full Text] [Related]
5. Cardiac Computed Tomography for Personalized Management of Patients With Type 2 Diabetes Mellitus.
Cardoso R; Dudum R; Ferraro RA; Bittencourt M; Blankstein R; Blaha MJ; Nasir K; Rajagopalan S; Michos ED; Blumenthal RS; Cainzos-Achirica M
Circ Cardiovasc Imaging; 2020 Sep; 13(9):e011365. PubMed ID: 32900225
[TBL] [Abstract][Full Text] [Related]
6. Diabetic stress: new triumphs and challenges to maintain vascular longevity.
Maiese K
Expert Rev Cardiovasc Ther; 2008 Mar; 6(3):281-4. PubMed ID: 18327989
[No Abstract] [Full Text] [Related]
7. Most important advances in preventive cardiology during this past decade: Viewpoint from the American Society for Preventive Cardiology.
Wong ND; Toth PP; Amsterdam EA;
Trends Cardiovasc Med; 2021 Jan; 31(1):49-56. PubMed ID: 31882264
[TBL] [Abstract][Full Text] [Related]
8. [Diabetes mellitus and coronary artery disease. Update on diagnosis and drug therapy].
Marx N; Blessing E
Dtsch Med Wochenschr; 2007 May; 132(19):1034-8. PubMed ID: 17476633
[No Abstract] [Full Text] [Related]
9. Diabetes Mellitus and Its Cardiovascular Complications: New Insights into an Old Disease.
Sardu C; De Lucia C; Wallner M; Santulli G
J Diabetes Res; 2019; 2019():1905194. PubMed ID: 31236416
[No Abstract] [Full Text] [Related]
10. Following the LEADER - why this and other recent trials signal a major paradigm shift in the management of type 2 diabetes.
Kosiborod M
J Diabetes Complications; 2017 Feb; 31(2):517-519. PubMed ID: 27839923
[TBL] [Abstract][Full Text] [Related]
11. Lessons from a cardiovascular outcome trial with liraglutide in type 2 diabetes.
Kim HJ; Kim DJ
J Diabetes Investig; 2017 Jul; 8(4):431-433. PubMed ID: 27930863
[No Abstract] [Full Text] [Related]
12. [Type 2 diabetes mellitus and cardiovascular risk factors: is comprehensive treatment required?].
Nadal JF; Gutiérrez PC
Med Clin (Barc); 2013 Sep; 141 Suppl 2():7-13. PubMed ID: 24444518
[TBL] [Abstract][Full Text] [Related]
13. Controlled trial of effect of documented cardiovascular risk scores on prescribing.
Hall LM; Jung RT; Leese GP
BMJ; 2003 Feb; 326(7383):251-2. PubMed ID: 12560273
[No Abstract] [Full Text] [Related]
14. Exercise training improves glycemic control in long-standing insulin-treated type 2 diabetic patients.
De Feyter HM; Praet SF; van den Broek NM; Kuipers H; Stehouwer CD; Nicolay K; Prompers JJ; van Loon LJ
Diabetes Care; 2007 Oct; 30(10):2511-3. PubMed ID: 17626892
[No Abstract] [Full Text] [Related]
15. New drugs and clinical trials in diabetes and hypertension.
Nilsson P
Exp Clin Endocrinol Diabetes; 1997; 105 Suppl 2():64-9. PubMed ID: 9288549
[TBL] [Abstract][Full Text] [Related]
16. Treating the cardiometabolic syndrome: an opportunity to provide comprehensive cardiovascular risk reduction.
Basile J; Houston M; Ferrario CM
J Cardiometab Syndr; 2006; 1(5):358-61. PubMed ID: 17679795
[No Abstract] [Full Text] [Related]
17. Cardiovascular Risk and Risk Factor Management in Type 2 Diabetes Mellitus: A Population-Based Cohort Study Assessing Sex Disparities.
Wright AK; Kontopantelis E; Emsley R; Buchan I; Mamas MA; Sattar N; Ashcroft DM; Rutter MK
Circulation; 2019 Jun; 139(24):2742-2753. PubMed ID: 30986362
[TBL] [Abstract][Full Text] [Related]
18. Diabetes and cardiovascular disease: what have we learned in 2012?
Cunningham GR
Tex Heart Inst J; 2013; 40(3):290-2. PubMed ID: 23914022
[No Abstract] [Full Text] [Related]
19. Baseline characteristics of the patient population in the Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)-TIMI 53 trial.
Mosenzon O; Raz I; Scirica BM; Hirshberg B; Stahre CI; Steg PG; Davidson J; Ohman P; Price DL; Frederich B; Udell JA; Braunwald E; Bhatt DL
Diabetes Metab Res Rev; 2013 Jul; 29(5):417-26. PubMed ID: 23564755
[TBL] [Abstract][Full Text] [Related]
20. New advances in the management of insulin resistance in type 2 diabetes. Introduction.
Campbell IW; Charbonnel B
Int J Clin Pract Suppl; 2001 Sep; (121):3. PubMed ID: 11594242
[No Abstract] [Full Text] [Related]
[Next] [New Search]
